Gain Therapeutics Inc (GANX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Gain Therapeutics Inc (GANX) has a cash flow conversion efficiency ratio of -0.249x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.62 Million) by net assets ($18.56 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see GANX market cap overview for the company's overall valuation and market capitalisation.
Gain Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Gain Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Gain Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Gain Therapeutics Inc ranked by their cash flow conversion efficiency. See GANX operating cash to total liabilities to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Kron Telekomunikasyon Hizmetleri AS
IS:KRONT
|
0.156x |
|
IT City Public Company Limited
BK:IT
|
0.008x |
|
Canna Global Acquisition Corp
NYSE:CNGL
|
-0.413x |
|
Popular Vehicles and Services Limited
NSE:PVSL
|
-0.018x |
|
Cps Technologies
NASDAQ:CPSH
|
-66.268x |
|
Shotspotter Inc
NASDAQ:SSTI
|
0.062x |
|
Birlesim Muhendislik Isitma Sogutma Havalandirma Sanayi & Ticaret Sirketi AS
IS:BRLSM
|
-0.179x |
|
Renergen Ltd.
JSE:REN
|
-0.171x |
Annual Cash Flow Conversion Efficiency for Gain Therapeutics Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Gain Therapeutics Inc from 2018 to 2025. View current stock price of Gain Therapeutics Inc for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $18.56 Million | $-18.47 Million | -0.995x | +61.32% |
| 2024-12-31 | $7.34 Million | $-18.87 Million | -2.572x | -71.45% |
| 2023-12-31 | $12.58 Million | $-18.87 Million | -1.500x | -92.74% |
| 2022-12-31 | $18.88 Million | $-14.69 Million | -0.778x | -119.12% |
| 2021-12-31 | $34.82 Million | $-12.37 Million | -0.355x | +32.02% |
| 2020-12-31 | $6.20 Million | $-3.24 Million | -0.522x | -112.58% |
| 2019-12-31 | $-449.86K | $-1.87 Million | 4.154x | +430.50% |
| 2018-12-31 | $-950.91K | $-744.51K | 0.783x | -- |
About Gain Therapeutics Inc
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. The company's drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and t… Read more